Patents Examined by Joseph F. Murphy
-
Patent number: 6803448Abstract: A novel GBS toxin receptor, and methods for its preparation and use are provided. GBS toxin receptor polynucleotides and polypeptides are provided as well as detection, screening, and therapeutic methods and pharmaceutical compositions involving such polynucleotides and polypeptides.Type: GrantFiled: July 21, 1999Date of Patent: October 12, 2004Assignee: Vanderbilt UniversityInventors: Carl G. Hellerqvist, Changlin Fu
-
Patent number: 6797811Abstract: The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also provided are assays utilizing the polynucleotides which facilitate the identification of ligands and modulators of the chemokine receptors. Receptor fragments, ligands, modulators, and antibodies are useful in the detection and treatment of disease states associated with the chemokine receptors such as atherosclerosis, rheumatoid arthritis, tumor growth suppression, asthma, viral infection, AIDS, and other inflammatory conditions.Type: GrantFiled: December 20, 1996Date of Patent: September 28, 2004Assignee: Icos CorporationInventors: Patrick W. Gray, Vicki L. Schweickart, Carol J. Raport
-
Patent number: 6794161Abstract: This invention relates to novel potassium channels and genes encoding these channels. More specifically the invention provides isolated polynucleotides encoding the KCNQ4 potassium channel, cells transformed with these polynucleotides, transgenic animals comprising genetic mutations, and the use of the transformed cells and the transgenic animals for the in vitro and in vivo screening of drugs affecting KCNQ4 containing potassium channels.Type: GrantFiled: January 27, 2000Date of Patent: September 21, 2004Assignee: NeuroSearch A/SInventor: Thomas J. Jentsch
-
Patent number: 6790626Abstract: The present invention concerns a new receptor having a preference for pyrimidine nucleotides, preferably UTP, or purine nucleotides and UDP, and which has an amino acid sequence having more than 60% homology with the amino acid sequence shown in FIG. 1.Type: GrantFiled: November 12, 1998Date of Patent: September 14, 2004Assignee: Euroscreen S.A.Inventors: Didier Communi, Sabine Pirotton, Marc Parmentier, Jean-Marie Boeynaems
-
Patent number: 6787355Abstract: This invention relates to multipotent neural stem cells, purified from the peripheral nervous system of mammals, capable of differentiating into neural and non-neural cell types. These stem cells provide an accessible source for autologous transplantation into CNS, PNS, and other damaged tissues.Type: GrantFiled: September 25, 2000Date of Patent: September 7, 2004Assignee: McGill UniversityInventors: Freda D. Miller, Andrew Gloster, Jean Toma
-
Patent number: 6783952Abstract: Soluble &agr;2&dgr; sub-type polypeptides. Methods for cloning, expression and purification of freely soluble &agr;2&dgr; subtype polypeptides. A method for the screening of ligands which bind to soluble &agr;2&dgr; subtype polypeptides.Type: GrantFiled: September 16, 1999Date of Patent: August 31, 2004Assignee: Warner-Lambert CompanyInventors: Jason Peter Brown, François Bertelli
-
Patent number: 6777536Abstract: The present invention relates to the discovery of a novel EPH receptor ligand, referred to hereinafter as “Elf-1”, which protein has apparently broad involvement in the formation and maintenance of ordered spatial arrangements of differentiated tissues in vertebrates, and can be used to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: GrantFiled: February 27, 1995Date of Patent: August 17, 2004Assignee: President and Fellows of Harvard CollegeInventors: John G. Flanagan, Hwai-Jong Cheng
-
Patent number: 6770742Abstract: The present invention concerns the use of inhibitors for the treatment and/or prophylaxis of diseases which are the consequence of increased receptor tyrosine kinase activity, particularly cancer. The use is particularly directed towards inhibition or lowering of the overexpression and/or altered activity of receptor tyrosine kinases (RTKs). In particular, this altered activity of receptor tyrosine kinase can be triggered by a mutation of FGFR-4, wherein this mutation is in particular a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic amino acid for a hydrophilic amino acid. The invention further concerns the use of an inhibitor directed against FGFR-4, for the treatment and/or prophylaxis of cancer. Furthermore, the invention concerns a mutated FGFR-4, which leads to overexpression and/or altered activity in cells. Finally, the invention concerns a DNA and RNA sequence of a mutated FGFR-4 molecule.Type: GrantFiled: September 7, 2000Date of Patent: August 3, 2004Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.Inventors: Axel Ullrich, Johannes Bange, Pjotr Knyazev
-
Patent number: 6767995Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: July 11, 2001Date of Patent: July 27, 2004Assignee: Genentech, Inc.Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
-
High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
Patent number: 6762290Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to a VEGF receptor. Included in the invention are specific RNA ligands to a VEGF receptor identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of a VEGF receptor with VEGF.Type: GrantFiled: July 29, 1999Date of Patent: July 13, 2004Assignee: Gilead Sciences, Inc.Inventors: Nebojsa Janjic, Larry Gold -
Patent number: 6750200Abstract: The present invention provides a family of peptides based upon the M2GlyR sequence. These peptides are derivatives of the M2GlyR sequence and can be modified at their ends to include a plurality of polar amino acid residues to enhance their solubility. Particularly preferred derivatives include portions of the M2GlyR sequence which are palindromic to another portion of the peptide or to the M2GlyR sequence itself. Preferably these portions are at least 7 amino acid residues in length. Peptides embraced by the present invention are characterized by having greater effects on the transepithelial electrical resistance of cells at lower concentrations. Peptides of the present invention have been shown to increase Isc in MDCK epithelial cell monolayers with half maximal effects observed at or below 30 &mgr;M, a nearly 10-fold improvement over any peptide previously characterized in the M2GlyR family.Type: GrantFiled: November 9, 2000Date of Patent: June 15, 2004Assignee: Kansas State University Research FoundationInventors: John M. Tomich, Takeo Iwamoto, James R. Broughman, Bruce D. Schultz
-
Patent number: 6723522Abstract: The present invention relates to a protein having a Na+—HCO3− cotransporter activity and a DNA encoding it. The present protein and the present DNA can be used as or for [1] obtaining an antibody and antiserum, [2] constructing an expression system for the present protein, [3] development of a system for measuring the activity of a Na+—HCO3− cotransporter and screening of a drug candidate compound using the same expression system, [4] performing drug design based on the steric structure of a Na+—HCO3− cotransporter protein, [5] a reagent for making a probe or a PCR primer in gene diagnosis, [6] making a transgenic animal, or [7] a composition for gene prevention and/or treatment.Type: GrantFiled: June 20, 2001Date of Patent: April 20, 2004Assignee: Takeda Chemical Industries, Ltd.Inventors: Hiroyuki Kimura, Tomohiro Kawamoto, Hidekazu Sawada
-
Patent number: 6723535Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: July 16, 2001Date of Patent: April 20, 2004Assignee: Genentech, Inc.Inventors: Avi Ashkenazi, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Ellen Filvaroff, Sherman Fong, Wei-Qiang Gao, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Ivar J. Kljavin, Jennie P. Mather, James Pan, Nicholas F. Paoni, Margaret Ann Roy, Timothy A. Stewart, Daniel Tumas, P. Mickey Williams, William I. Wood
-
Patent number: 6716587Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.Type: GrantFiled: March 22, 2002Date of Patent: April 6, 2004Assignee: Immunex CorporationInventors: Bruce A. Mosley, David J. Cosman, Linda S. Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
-
Patent number: 6713053Abstract: The use of interleukin 7 or T cells pre-incubated in the presence of IL-7 for preparing a drug or pharmaceutical composition for treating an auto-immune disease, particularly an auto-immune disease induced by a defect in CD4+ T cell immunoregulation, is disclosed.Type: GrantFiled: August 18, 1998Date of Patent: March 30, 2004Assignee: Sanofi-SynthelaboInventors: Jean Francois Bach, Jean Marc Gombert, Andre Herbelin, Michel Morre
-
Patent number: 6709839Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.Type: GrantFiled: September 24, 1999Date of Patent: March 23, 2004Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ying Luo, Helena Mancebo
-
Patent number: 6709831Abstract: This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.Type: GrantFiled: September 24, 1999Date of Patent: March 23, 2004Assignee: Synaptic Pharmaceutical CorporationInventors: Christophe P. G. Gerald, Kenneth A. Jones, James A. Bonini, Beth E. Borowsky, Douglas A. Craig
-
Patent number: 6703222Abstract: DNA encoding a soluble LDL receptor protein, is provided, as are vectors, cell lines and processes for the production of the protein, mutein or fragment. The soluble LDL receptor protein, and its muteins and fragments, are useful in protection of mammals against viral infections.Type: GrantFiled: April 4, 2001Date of Patent: March 9, 2004Assignee: Yeda Research and Development Co. Ltd.Inventors: Menachem Rubinstein, Daniela Novick, Nathan Tal, Dina G. Fischer
-
Patent number: 6699660Abstract: The present invention provides methods and materials related to immediate early genes. Specifically, the invention provides isolated immediate early gene nucleic acid, cells that contain isolated immediate early gene nucleic acid, substantially pure polypeptides encoded by immediate early gene nucleic acid, and antibodies having specific binding affinity for a polypeptide encoded by immediate early gene nucleic acid. In addition, the invention provides cDNA libraries enriched for immediate early genes cDNAs, isolated nucleic acid derived from such cDNA libraries, and methods for treating conditions related to a deficiency in a neuron's immediate early gene responsiveness to a stimulus.Type: GrantFiled: February 5, 1999Date of Patent: March 2, 2004Assignee: The Johns Hopkins University School of MedicineInventors: Paul F. Worley, Anthony Lanahan, Bernhard Goetz, Holger Hiemisch, Rohini Kuner, Sigrid Scheek, Karoly Nikolich, Eugene Zhukovsky
-
Patent number: 6699687Abstract: The present invention provides polypeptide and polynucleotides encoding fluorescent indicators having inserted within a fluorescent moiety a sensor polypeptide. Also provided are methods of using the fluorescent indicator. Circularly permuted fluorescent polypeptides and polynucleotides are also provided.Type: GrantFiled: May 21, 1999Date of Patent: March 2, 2004Assignee: The Regents of the University of CaliforniaInventors: Roger Y. Tsien, Geoffrey Baird